Ranolazine terminates atrial flutter and fibrillation in a canine model
- 1 September 2014
- journal article
- Published by Elsevier in Heart Rhythm
- Vol. 11 (9) , 1592-1599
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillationEP Europace, 2012
- Electrophysiologic basis for the antiarrhythmic actions of ranolazineHeart Rhythm, 2011
- Vanoxerine, a New Drug for Terminating Atrial Fibrillation and FlutterJournal of Cardiovascular Electrophysiology, 2010
- Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non–ST-Segment–Elevation Acute Coronary SyndromeCirculation, 2007
- Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogsEuropean Journal of Pharmacology, 2006
- AZD7009:Journal of Cardiovascular Electrophysiology, 2004
- Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe anginaJACC, 2004
- Simultaneous Multisite Mapping Studies During Induced Atrial Fibrillation in the Sterile Pericarditis ModelCirculation, 1997
- Mechanism of interruption of atrial flutter by moricizine. Electrophysiological and multiplexing studies in the canine sterile pericarditis model of atrial flutter.Circulation, 1994
- A new animal model of atrial flutterJACC, 1986